Category: Zacks Small Cap Research

1606162636481620 / 810 POSTS
By Brian Marckx, CFAOTC:SMLRREAD THE FULL SMLR RESEARCH REPORTQ2 2018 Results: Huge Beat to Our #s. Huge Upward Revisions to Our Model and Price Target…Semler’s (OTC:SMLR) results in each of the last few quarters have indicated that the company could ...
By Lisa ThompsonNASDAQ:RVLTREAD THE FULL RVLT RESEARCH REPORTRevolution Lighting Technologies (NASDAQ:RVLT) missed its revenue guidance by reporting Q2 revenues of $36.4 million versus $43.4 million a year ago, down 16%. A few large opportunities tha ...
By John Vandermosten, CFANASDAQ:RXIIOn August 1st RXi Pharmaceuticals (NASDAQ:RXII) issued a press release announcing positive results from their RXI-109-1501 Phase I/II trial for retinal scarring. The primary outcome for the trial was to determine t ...
OTC:CVSISan Diego, California-based CV Sciences, Inc. (OTC:CVSI) manufactures hemp-based phytocannabinoids including cannabidiol (CBD) oil and also develops specialty pharmaceutical therapeutics. The company reported 2Q18 results yesterday that refle ...
By Brian Marckx, CFANASDAQ:VIVEREAD THE FULL VIVE RESEARCH REPORTOn July 30th FDA issued a Safety Communications letter warning against the use of “Energy-Based Devices to Perform Vaginal ‘Rejuvenation’ of Vaginal Cosmetic Procedures”. The purpose of ...
By Lisa ThompsonNASDAQ:OIIMREAD THE FULL OIIM RESEARCH REPORTO2Micro (NASDAQ:OIIM) reported Q2 2018 revenues of $15.2 million, up 8% sequentially, and 5% year over year and within the range of guidance of up 2-10%. The company returned to growth afte ...
Allogene Therapeutics, Grail, Brii BioSciences, Moderna Therapeutics, Precision BioSciences, Kaleido Biosciences, Constellation Pharmaceuticals, Stealth BioTherapeutics, PACT Pharma, Beam Therapeutics.Healthcare was 15% of total deal activity i ...
OTC:ZENONASDAQ:CTXRCitius Pharmaceuticals, Inc. (NASDAQ:CTXR) is a specialty pharmaceutical company focused on the development and commercialization of proprietary formulations of already-approved drugs which target large and growing markets.   By re ...
By Brian Marckx, CFANASDAQ:EYEGREAD THE FULL EYEG RESEARCH REPORTFDA Approves IDEs for Both OBG Clinical Studies; i.e. the second PRK pilot study and initial PE pilot studyAs we noted in our Q1 ’18 earnings update in late-May, Eyegate Pharmaceuticals ...
By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT Financial UpdateOn July 23, 2018, MediciNova, Inc. (NASDAQ:MNOV) filed form 10-Q with financial results for the second quarter of 2018. As expected, the company did not report any rev ...
1606162636481620 / 810 POSTS